ArticleLiver international : official journal of the International Association for the Study of the Liver2026
Characteristics and Clinical Outcomes in Patients With Cirrhosis due to MASLD in Sweden.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lived Experience, Concerns, and Support Needs of Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Qualitative Study.Healthcare (Basel, Switzerland) · 2026Article
- Risk analysis of the association between lactate-to-hematocrit ratio and poor prognosis in critical patients with cirrhosis.Medicine · 2026Article
- Characteristics and Clinical Outcomes in Patients With Cirrhosis due to MASLD in Sweden.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThere is limited real-world data on the prognosis of patients with cirrhosis due to metabolic dysfunction-associated steatotic liver disease (MASLD). We sought to describe the characteristics and assess the clinical course of MASLD-cirrhosis.
methodsA Swedish register-based cohort including 2318 patients with compensated and 1339 with decompensated cirrhosis due to MASLD from 2001 to 2020 was analysed. Incidence rates of severe clinical events including decompensated cirrhosis, liver transplantation or overall mortality were estimated. We further compared the results using a clinical cohort of 293 patients with MASLD- cirrhosis from three University Hospitals.
resultsOverall, 55.7% patients with compensated cirrhosis (median age 70, 43.6% female, 88.7% type 2 diabetes [T2D]) developed severe clinical events during a median follow-up of 1.1 years. The incidence rate was 78.5/1000 person-year (PY), 6.8/1000 PY and 182.0/1000 PY for decompensation, liver transplantation and death, respectively. Among 1399 patients with decompensated cirrhosis (median age 72, 41.1% female, 86% T2D), ascites (74.6%) was the most frequent initial events. 59.7% experienced death or transplantation with a median follow-up of 0.58 years. The incidence rate was 14.0/1000 PY for liver transplantation and 353.2/1000 PY for overall death. Estimates were similar in the clinical cohort but lower overall mortality were observed (IR = 63.1/1000 PY in compensated cirrhosis and 188.2/1000 PY in decompensated events).
conclusionsThis study describes the clinical characteristics and the natural history of patients with MASLD-cirrhosis by compensation status in Sweden, providing estimates for important outcomes that may be useful for patient prognostication and clinical trial design.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.